Follow CAP on Social Media

Listen to the CAP Podcast

In a Potentially Troubling Development for Africa, Sinovac Did Not Perform Well in Early Test Against Omicron Variant

A healthcare worker holds up a SINOVAC Covid-19 vaccine before administering it on a minor during the Numolux/SINOVAC Peadiatric Covid-19 Vaccine Clinical Trial at the University in Pretoria, on September 10, 2021. Phill Magakoe / AFP

Researchers at the University of Hong Kong (HKU) found that people inoculated with two doses of Sinovac’s COVID-19 vaccine did not produce sufficient detectable levels of antibodies needed to fend off the new highly-infectious Omicron variant.

A third injection did generate some antibodies but researchers cautioned that it is still too early to tell if the extra booster would be enough to prevent infection.

This marketing content will be shown in place of your protected content to anyone who is not allowed to read the post…

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Africa Project?

Independent

The CAP is passionately independent, non-partisan and does not advocate for any country, company or culture.

News

A carefully curated selection of the day’s most important China-Africa stories. Updated 24 hours a day by human editors. No bots, no algorithms.

Analysis

Diverse, often unconventional insights from scholars, analysts, journalist and a variety of stakeholders in the China-Africa discourse.

Networking

A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.